A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP Policy Panel OKs FY2025 Budget Guidelines, Lower Cap Likely for “Natural Increase”
July 24, 2024
-
BUSINESS Axcelead-Teijin JV Anticipates Synergies in Common Disease Areas, Pipelines
July 23, 2024
-
BUSINESS Terumo to End Sale of HeartSheet after Panel’s Thumbs-Down
July 22, 2024
-
REGULATORY Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
-
REGULATORY MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
-
REGULATORY Debates on FY2025 Off-Year Price Revision Officially Set Sail at Chuikyo
July 18, 2024
-
BUSINESS Insmed Set to Double Japan Staff by 2025-End as It Gears Up for Brensocatib Debut
July 17, 2024
-
BUSINESS LTL, Cheplapharm Envision Heightened Opportunities for LLP Takeovers under Elective Care Scheme
July 16, 2024
-
BUSINESS Meiji Paints Consortium Plan of Its Own, Woos Generic Peers to Join Scheme
July 16, 2024
-
BUSINESS Chiesi Joins Japan Rare Disease Market, Shoots for 10 Billion Yen Sales by 2030
July 12, 2024
-
BUSINESS FY2023 Logs Gyration in COVID Drug Sales, Stark Contrast for Ronapreve, Lagevrio
July 11, 2024
-
REGULATORY Japan Wants to Spur Regulatory Use of RWD, but Still Puts Weight on RCTs
July 10, 2024
-
REGULATORY PMDA to Push Simultaneous Development of Pediatric Drugs via New Consultation Center
July 9, 2024
-
BUSINESS Moderna Medical Chief Voices Excitement for Flu-COVID Jab; Japan PIII Set to Kick Off by Year’s End
July 9, 2024
-
REGULATORY MHLW Proposes New Scheme for Development Requests to Fight Drug Loss
July 8, 2024
-
REGULATORY Panelists Wary of Proposed Switch of Generic GMP Inspection Authority to PMDA
July 8, 2024
-
REGULATORY Minister Nudges Generic Product Consolidation, Pitches “5 Makers per API”
July 5, 2024
-
BUSINESS 32 Pharma Execs Snag 100 Million Yen-Plus in FY2023, Takeda Sweeps Top 3
July 4, 2024
-
BUSINESS Chugai Grabs Japan’s Best-Paying Pharma Crown Yet Again: Jiho Tally
July 3, 2024
-
REGULATORY New ICH Topic on RWD to Be Proposed towards Its Use in Regulatory Review
July 2, 2024
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…